Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Shareholder Meeting (November 2020)
13 slides from Atomo Diagnostics's shareholder meeting presentation, Nov 4, 2020
Slide 1: Managing Director's AGM Presentation
Atomo Diagnostics Limited 701 – 703 Parramatta Road Leichhardt NSW 2040 Australia MANAGING DIRECTOR’S AGM PRESENTATION 4 NOVEMBER 2020 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 2: Introduction
INTRODUCTION Atomo Diagnostics Limited (ASX: AT1) is a medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market Headquartered in Australia with global operations, Atomo develops, manufactures and sells innovative patented products that s
Slide 3: Corporate Snapshot
C O R P O R AT E S N A P S H O T KEY FINANCIAL DETAILS SHARE PRICE PERFORMANCE 0.6 ASX code AT1 0.5 Share price (30/10/20) $0.33 0.4 Shares on issue 563.3m 0.3 Options on issue 29.7m IPO @ 20c Market cap* $189m 0.2 Current cash (30/9/20) $26.4m 0.1 *Undiluted 0 16-Apr 16-May 16-Jun 16-Jul 16-Aug 16-
Slide 4: Financial Highlights
FINANCIAL HIGHLIGHTS Q1 FY21 FY20 Key metrics Annual Sales Revenue ($m) $m Cash receipts from customers 3.04 Net cash from operating activities 0.34 Net cash from investing activities (1.08) Net cash from financing activities 0.12 Cash at end of the period 26.35 • Revenue in FY20 of $5.37 million ~1
Slide 5: Patent Protected Solutions
PAT E N T P R O T E C T E D S O L U T I O N S Traditional ‘bits in a box’ kits Atomo’s fully integrated user-friendly solutions Standard lateral flow ‘bits in a box’ test kits Atomo has developed a range of The test process can be completed typically contain multiple components unique, integrated de
Slide 6: What Our Customers Say
WHAT OUR CUSTOMERS SAY “These solutions reduce error rates “We believe the incorporation of novel and improve care and have significant Atomo technology will improve ease of commercial potential in both the use and accuracy, allowing for broader developing world and in developed acceptance in outpat
Slide 7: Progress During FY21
PROGESS DURING FY21 COVID-19 antibody test deal with US Co. Access Bio completed for North America Initial order received from Access Bio for 2 containers (~250,000 devices) for production builds to support pending product launch in the US Import permit received by DIVOC for Indian evaluation
Slide 8: Anticipated Progress During H1 FY21
A N T I C I PAT E D P R O G E S S D U R I N G H . 2 F Y 2 1 • Atomo COVID-19 antibody and antigen rapid tests to be launched in Australia • The Atomo / Access Bio CareStart COVID-19 rapid test to be launched in North America • US business and dedicated resources to be set up to support increased foc
Slide 9: A Sector Seeing Growth & Transformation
A S E C T O R S E E I N G G R O W T H & T R A N S F O R M AT I O N A long-term transition to decentralised healthcare An emerging high growth opportunity delivery, accelerated by the global COVID-19 Pandemic This is driving significant growth in the global medical The U.S. telehealth industry is for
Slide 10: Smart Solutions
SMART SOLUTIONS Pascal Digital Solution User App / eHealth • Compatible with existing Pascal products, this low • Designed initially to support cost disposable clip-in reader can measure line professional users screen for intensity, record time and place of test and meets COVID-19 in point of care s
Slide 11: Increasing Capacity
I N C R E A S I N G C A PA C I T Y Continued investment in manufacturing capacity expansion * Next gen blister manufacturing We have commenced process improvement and build for additional automated blisters machines to support the expansion of Pascal and Elion in OEM markets, as well as providing ‘b
Slide 12: Strategic Priorities
S T R AT E G I C P R I O R I T I E S Continued expansion of device sales revenues via new OEM contracts in existing lateral flow rapid test markets. To support that Atomo has appointed a US based Business Development resource and has commenced an OEM engagement program. Set up a US footprint with co
Slide 13: John Kelly, Managing Director
John Kelly Managing Director john.kelly@atomodiagnostics.com +61 401 922 279 atomodiagnostics.com
Atomo Diagnostics — Shareholder Meeting (November 2020) on 6ix